Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237636 | 1.00 | FUCA1 (0.45) | FUCA1SIGMAR1ACHETHRBMC4R | |
| SCHEMBL1237635 | 1.00 | FUCA1 (0.45) | FUCA1SIGMAR1ACHETHRBMC4R | |
| SCHEMBL3884231 | 0.90 | FUCA1 (0.54) | FUCA1THRBS1PR1S1PR5CYP1A2 | |
| SCHEMBL3880527 | 0.90 | FUCA1 (0.54) | FUCA1THRBS1PR1S1PR5CYP1A2 | |
| SCHEMBL3885157 | 0.90 | DPP4 (0.41) | FUCA1SIGMAR1ACHETHRBMC4R | |
| SCHEMBL20131397 | 0.87 | GBA1 (0.43) | CYP2C19GBA1 | |
| SCHEMBL2631789 | 0.87 | GBA1 (0.43) | CYP2C19GBA1 | |
| SCHEMBL4297275 | 0.84 | HTR4 (0.41) | FUCA1S1PR1S1PR5DRD2DRD3 | |
| SCHEMBL13631038 | 0.84 | FUCA1 (0.35) | FUCA1SIGMAR1ACHETHRBS1PR1 | |
| SCHEMBL4297271 | 0.84 | HTR4 (0.41) | FUCA1S1PR1S1PR5DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025099451-A1 | NEW COMPOUNDS AND METHODS | Transition Bio Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| EP-3238738-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2017-11-01 | — | — | EP | disclosed |
| EP-2355658-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9220683-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-12-29 | — | — | US | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010054406-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | FUCA1 1310/4885SIGMAR1 466/4885ACHE 1581/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | FUCA1 1450/4885SIGMAR1 462/4885ACHE 1575/4885 |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, ABCB4, LCAT | FUCA1 1153/4885SIGMAR1 2216/4885ACHE 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.